› 2m86

Solution NMR

Solution structure of Hdm2 with engineered cyclotide

Released:
DOI: 10.2210/pdb2m86/pdb
PDB entry 2m86 coloured by chain, ensemble of 10 models, front view.
PDB entry 2m86 coloured by chain, ensemble of 10 models, side view.
PDB entry 2m86 coloured by chain, ensemble of 10 models, top view.
Source organisms:
Primary publication:
In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide.
Ji Y, Majumder S, Millard M, Borra R, Bi T, Elnagar AY, Neamati N, Shekhtman A, Camarero JA
J Am Chem Soc 135 11623-11633 (2013)
PMID: 23848581

Function and Biology Details

Reaction catalysed: 
S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine
Biochemical function:
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
hetero dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-162980 (preferred)
Entry contents:
2 distinct polypeptide molecules
Macromolecules (2 distinct):
MCo-PMI Chain: A
Molecule details ›
Chain: A
Length: 51 amino acids
Theoretical weight: 5.29 KDa
Source organism: synthetic construct
Expression system: Escherichia coli
Structure domains: R-elafin
E3 ubiquitin-protein ligase Mdm2 Chain: B
Molecule details ›
Chain: B
Length: 129 amino acids
Theoretical weight: 14.71 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: Q00987 (Residues: 17-125; Coverage: 22%)
  • Best match: Q00987-8 (Residues: 1-64)
Gene name: MDM2
Sequence domains: SWIB/MDM2 domain
Structure domains: SWIB/MDM2 domain

Ligands and Environments

No bound ligands
No modified residues

Experiments and Validation Details

Entry percentile scores
Chemical shift assignment: 46%
Refinement method: DGSA-distance geometry simulated annealing
Expression system: Escherichia coli

Quick links

Citations

40 review citations

Drugging the p53 pathway: understanding the route to clinical efficacy.
Khoo et al. (2014)
39 more

3 mentions without citation

Using backbone-cyclized Cys-rich polypeptides as molecular scaffolds to target protein-protein interactions.
Chaudhuri et al. (2019)
2 more